Longeveron (LGVN) announced the pricing of a public offering of 5.88M of the company’s Class A common stock, together with short-term warrants to purchase up to 14.71M shares of Class A common stock at a combined public offering price of 85c per share of Class A common stock and accompanying short-term warrants. The short-term warrants will have an exercise price of 85c per share and will be immediately exercisable upon issuance for a period of twenty-four months following the date of issuance. Certain board members and insiders of the company are participating in the offering on the same terms and conditions. The offering is expected to close on or about August 11, subject to satisfaction of customary closing conditions. The gross proceeds to the company from the offering, before deducting the placement agent’s fees and other offering expenses payable by the company, are expected to be approximately $5.0M. The potential additional gross proceeds to the company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $12.5M. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Longeveron files to sell 3.85M shares of Class A common stock
- Longeveron licenses patent for stem cell technology from University of Miami
- Longeveron Gains FDA Approval for Laromestrocel Trial
- Longeveron Receives Buy Rating: Promising Pipeline and Strategic Expansion into Pediatric Cardiomyopathy
- Longeveron announces FDA approval of IND application for laromestrocel study
